Tagged with Clinical Trials

MEA CTI EMEA Managing Director Alaa Assem is a physician, ophthalmologist and MBA holder with over 30 years of experience in pharma and clinical research organisations. Since joining CTI, he has strengthened the company’s presence in the Middle East, focusing on rare disease, gene and cell therapy, oncology, and transplantation. CTI…

MEA As healthcare systems across the GCC accelerate their focus on innovation, access, and advanced therapies, Novartis is positioning the region at the centre of its long-term strategy. Mohamed Ezz Eldin shares how global priorities are translated into local execution, from rare disease care and genomics to clinical research and innovative…

MEA Biogen’s transformation into a rare disease-focused organisation is reshaping how innovation reaches patients in the GCC. Diederik Kok, the company’s GCC Head reflects on how global strategy translates into regional execution, from launching first-in-class therapies and navigating access for ultra-rare conditions, to building sustainable financing models, clinical research capacity, and…

Hong Kong Hong Kong is quietly re-engineering how clinical research is organised and delivered across one of the world’s most dynamic life-sciences regions. Through the Greater Bay Area International Clinical Trial Institute (GBAICTI), Hong Kong’s long-established academic and regulatory strengths are being connected with the scale, infrastructure, and talent of the wider…

UAE Dr Rania Alshami reflects on two decades in the Middle East and North Africa clinical research ecosystem, charting the region’s regulatory maturation, rare disease opportunities, and growing role in early-phase trials. She discusses patient access, genomics integration, sponsor engagement, and why MENA is emerging as a credible hub for innovation…

Taiwan Chung-Liang Shih, Taiwan’s Minister of Health and Welfare, brings extensive governmental experience from his tenure as Director General of the National Health Insurance Administration, where he led reforms to strengthen financial sustainability while expanding access to innovative medicines. His strategic vision focuses on structural healthcare reform, digital transformation, and preventative…

China Cancer drug development has produced an abundance of therapies, yet outcomes in solid tumours remain constrained by resistance and relapse. In this interview, Zaiqi Wang, Chairman and CEO of InxMed, explains why the company starts from tumour defence biology rather than individual targets, and how this perspective informs its combination…

Hong Kong As Hong Kong positions itself as a regional healthcare and clinical research hub within the Greater Bay Area, multinational pharma companies are being asked to play a more active role in shaping access to innovation, generating local data, and integrating the territory into global development programmes. Joaquim Antunes Lopes shares…

Argentina Has Argentina, for years one of the economic basket cases of Latin America, finally turned a corner? And is its pharma industry set for a bounce back?   Firebrand TV pundit-turned politician Javier Milei was elected President in late 2023 on a promise to slash public spending and state intervention.…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Insilico Medicine’s partnership with Hengtai Biotech to co-develop an AI-discovered NLRP3 inhibitor for CNS disorders and Ellipses Pharma’s licensing of a first-in-class B7H3 ADC from Innolake Biopharm. IPO filings by Dizal Pharmaceutical, Biosun Pharma, and Fosun Adgenvax highlight the…

Hong Kong Nearly two years on from our last conversation with Henry Yau, Hong Kong’s clinical trials narrative has shifted from institutional intent to operational execution. The managing director of the HKU Clinical Trials Centre reflects on how regulatory reform, ecosystem coordination, and on-the-ground capability are now aligning, repositioning clinical research as…

Global Bristol Myers Squibb (BMS), faced with patent expiries for its two largest historical revenue-generators, is racing to replace them. The US giant is re-entering the hot-again neuroscience space, as well as bringing forward cardiovascular, immunology, and oncology molecules, with management proclaiming that six of its pipeline assets boast multibillion-dollar potential.…